Senior Director, Medical Affairs, Solid Tumors

Senior Director, Medical Affairs, Solid Tumors

Join to apply for the Senior Director, Medical Affairs, Solid Tumors role at Lyell Immunopharma
.

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next‑generation cell therapies that can deliver increased response rates and longer duration of response.

We are a clinical‑stage company advancing a pipeline of next‑generation CAR T‑cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long‑lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T‑cell biology and its interaction with cancer.

In our quest to advance next‑generation CAR T‑cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission’s urgency. This role is a fully remote position.

• Strategic Leadership & Program Oversight
  • Serve as Lyell’s Medical Affairs lead for mCRC and future solid tumor programs, providing deep disease‑area expertise and independent strategic direction.
  • Partner closely with the SVP, Medical Affairs and the VP, Medical Affairs to shape and evolve the overall vision for Medical Affairs.
  • Lead the development and execution of the Medical Affairs strategy for solid tumors, aligned with corporate, clinical, and regulatory objectives.
  • Shape medical narrative, scientific platform, core claims, and evidence‑generation needs to support evolving program priorities.
  • Drive Medical Affairs contributions to launch readiness for solid tumor assets.
• External Engagement
  • Build and maintain strong professional relationships with Key Opinion Leaders (KOLs), investigators, and academic centers, specifically within the GI oncology and solid tumor communities.
  • Represent Lyell at key scientific congresses (e.g., ASCO, ESMO, GI ASCO) and advisory boards to facilitate scientific exchange.
  • Gather and synthesize external insights to shape Medical Affairs initiatives and support clinical development priorities.
• Medical Excellence & Communications
  • Oversee the development of medical narratives, scientific platforms, and publications strategy for the solid tumor portfolio.
  • Ensure compliant, high‑quality execution of medical communication initiatives and educational materials relevant to the colorectal cancer program.
  • Provide scientific training and guidance to internal teams and field medical staff to ensure consistency and accuracy of scientific messaging.
• Leadership & Governance
  • Demonstrate independent leadership in managing projects, resources, and potential direct reports or cross‑functional teams to meet program deliverables.
  • Ensure all Medical Affairs activities within the solid tumor program comply with legal, regulatory, and corporate standards.
  • Contribute to the development of governance frameworks and authorship policies as a senior member of the Medical Affairs team.

• MD, DO, Pharm
  
  D, or PhD required.
• Oncology specialty required; specific background in GI oncology or solid tumors strongly preferred.
• Minimum 8–10 years of pharmaceutical/biotech industry experience, with 5+ years in Medical Affairs.
• Extensive experience in oncology is required; prior experience in metastatic colorectal cancer, cell therapy, or immuno‑oncology is highly desirable.
• Proven track record of independently leading…